{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Stringent Complete Response (sCR) or better"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Complete Response (CR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Very Good Partial Response (VGPR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Partial Response (PR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Minimal Response (MR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Stable Disease (SD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Progressive Disease (PD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Not Evaluated"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Disease response and progression were determined by the investigator using the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). Overall response rate includes patients with a best response of PR of better. Stringent complete response (CR) includes immunophenotypic CR and molecular CR in addition to stringent CR.","groups":[{"description":"Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles","id":"OG000","title":"MRZ 0.5 mg/m^2"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Through study completion, an average of 6.09 weeks.","title":"Number of Patients Exhibiting a Given Overall Response as Determined by Investigator","type":"PRIMARY","unitOfMeasure":"participants"}